CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erb

  
    
  
  
    
      Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its 
      oncology candidate, CB1400, as a tumor reducing agent and has also 
      demonstrated the synergistic effect of this drug in combination with 
      both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.
    
    
      Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, “We 
      at Canopus are encouraged with the discovery of this new use for CB1400 
      to increase efficacy and reduce toxicity issues associated with 
      conventional chemotherapeutic agents.”
    
    
      CB1400, a former schistosomal drug, is currently in phase II clinical 
      development as an anti-mucositis preventative agent in patients 
      receiving radio- and/or chemotherapy treatment. Current anti-mucositis 
      drugs have shown tumor-protective properties. For this reason CB1400 was 
      evaluated by Canopus to determine its effect on tumor growth.
    
    
      In work carried out by the Harvard School of Dental Medicine, Boston, on 
      behalf of Canopus BioPharma, it was confirmed that CB1400 as a single 
      agent significantly reduces tumor growth. In an initial study, tumor 
      growth was inhibited by 48.8% in mice treated with cisplatin, the most 
      commonly used chemotherapy drug. CB1400 alone showed 62.3% tumor growth 
      inhibition while the combination of both compounds further increased 
      inhibition to 69.6%, thus confirming a synergistic effect between 
      cisplatin and CB1400. In addition, there was no evidence of toxicity 
      based on observations of survival and weight change in the mice and 
      there was no evidence that CB1400 protected the tumor.
    
    
      Cisplatin is a platinum-containing chemotherapeutic drug, administered 
      by IV injection which has been used for more than 30 years to treat 
      various forms of cancer. Enhanced efficacy with CB1400 may prevent the 
      development of drug resistance that is common with cisplatin.
    
    
      In a similar study, tumor growth was inhibited by 61% in mice treated 
      with cetuximab (Erbitux) alone. An almost 30% increase in efficacy was 
      observed with the addition of CB1400 to cetuximab, increasing tumor 
      inhibition to 89.4%, confirming a synergistic effect of combining the 
      two anti-tumor drugs. Similar to the cisplatin study, there was no 
      significant difference in mean weight or survival between the groups of 
      mice; and no toxicity was observed in this study.
    
    
      Cetuximab is a chimeric monoclonal antibody, an epidermal growth factor 
      receptor inhibitor used as a chemotherapeutic agent, administered by IV 
      injection for the treatment of various cancers. Enhancing the efficacy 
      of cetuximab may have potential in treating patients no longer 
      responding to traditional chemotherapy.
    
    
      About Canopus BioPharma, Inc.:
    
    
      Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the 
      safest, most cost effective and efficacious pharmaceutical products and 
      assay methods in the areas of infectious disease, radiation protection, 
      cancer, and addiction. With innovative science, proven research and 
      development leadership, and superior products and compounds, Canopus 
      BioPharma has, since 2001, been committed to becoming a market trend 
      setter in a new era of healthcare. In addition, the Company is a world 
      leader in the development of novel camelid antibody products to provide 
      unique avenues of progress and improvement in assay methods and 
      monitoring capabilities for physicians, patients and researchers, 
      initially for food chain protection applications. Canopus maintains 
      staff in Australia, South Africa, Ireland, Panama and the USA. 
      Additional information on the Company is available at www.canopusbiopharma.com.